Revance Therapeutics is a biotechnology company focused on developing innovative therapies for various medical conditions, primarily in the fields of aesthetics, neuromodulation, and pain management
The company specializes in creating advanced drug formulations and delivery technologies that aim to provide longer-lasting effects and improve patient outcomes. Through its proprietary products, Revance aims to address unmet medical needs while enhancing the quality of life for patients. The company's portfolio includes both aesthetic treatments and therapeutic applications, showcasing its commitment to innovation in the healthcare sector.
NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioAge Labs, Inc. (NASDAQBIOA), AstraZeneca PLC NASDAQ: AZNNASDAQAZN)(NASDAQ:FTAINASDAQFTAI, and Revance Therapeutics, Inc. (NASDAQ:RVNCNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
NEW YORK - February 3, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
NEW YORK - February 1, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
NEW YORK - January 31, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
NEW YORK - January 30, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioAge Labs, Inc. (NASDAQBIOA), Caribou Biosciences, Inc. NASDAQ: CRBUNASDAQCRBU)(NASDAQ:FTAINASDAQFTAI, and Revance Therapeutics, Inc. (NASDAQ:RVNCNASDAQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
NEW YORK - January 29, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of BioAge Labs, Inc. (NASDAQBIOA) and Revance Therapeutics, Inc. NASDAQ:RVNCNASDAQRVNC)
Crown Laboratories, Inc. (“Crown”) and Revance Therapeutics, Inc. (NASDAQRVNC) (“Revance”), today announced that, on January 17, 2025, they amended their previously announced Amended and Restated Merger Agreement (the “Second Amendment,” together with the Amended and Restated Merger Agreement, dated December 7, 2024, the “A&R Merger Agreement”).
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQRVNC) and certain of its officers.
NEW YORK - January 13, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
NEW YORK - January 11, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or “the Company”) (NASDAQRVNC) and certain of its officers.
Glancy Prongay & Murray LLP reminds investors of the upcoming March 4, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQRVNC) securities between February 29, 2024 and December 6, 2024, inclusive (the “Class Period”).
NEW YORK - January 10, 2025 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. (“Revance” or the “Company”) (NASDAQRVNC) on behalf of investors that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024 (the “Class Period”).
